Figure 1From: Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)Treatment response at a median follow-up of 3 months and 9 months after RTX treatment compared with baseline (BL). Changes in BVAS (A), daily prednisone dose (B), eosinophils (C), CRP concentrations (D), B-lymphocyte percentages (E), and IgE concentrations (F) are depicted. ***P < 0.001, **P < 0.01; *P < 0.05.Back to article page